{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:38:20Z","timestamp":1760834300586,"version":"build-2065373602"},"reference-count":42,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pierre Fabre, Paris, France","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,10,27]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The BEACON CRC randomised controlled trial (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02928224\">NCT02928224<\/jats:ext-link>) in BRAF-mutant metastatic colorectal cancer (mCRC) patients showed improved overall survival for the combination treatment of encorafenib (BRAF inhibitor) with cetuximab (EGFR inhibitor) compared with cetuximab with chemotherapy (FOLFIRI (folinic acid, fluorouracil and irinotecan) or irinotecan). We aimed to evaluate the cost-effectiveness of encorafenib with cetuximab in adult patients with BRAF-mutant mCRC after prior systemic therapy, from the perspective of the French healthcare system.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>A partitioned survival analysis model was developed to assess the cost-effectiveness of encorafenib with cetuximab using data from BEACON CRC (encorafenib with cetuximab and cetuximab with FOLFIRI or irinotecan). For two further comparator treatments (FOLFIRI alone and bevacizumab with FOLFIRI), a systemic literature review identified appropriate clinical trial data for indirect comparison. Piecewise modelling extrapolation was used to fulfil a lifetime horizon in the model. A discount rate of 2.5% was used. Treatment-emergent adverse events \u2265grade 3 with an incidence of \u22652% were included, as well as relative dose intensity and utility values.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcome measures<\/jats:title>\n                  <jats:p>The effectiveness outcomes of the model were expressed in terms of incremental life years gained and incremental quality-adjusted life years (QALY) gained. The cost-effectiveness of encorafenib with cetuximab was assessed using the incremental cost-effectiveness ratio (ICER). Results were presented probabilistically to account for parametric uncertainty. Deterministic and scenario analyses were conducted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The ICER for encorafenib with cetuximab versus cetuximab with FOLFIRI or irinotecan, FOLFIRI alone and bevacizumab with FOLFIRI was \u20ac69 823\/QALY, \u20ac70 421\/QALY and \u20ac72 336\/QALY, respectively. Encorafenib with cetuximab was considered cost-effective compared with the three comparators at a willingness to pay threshold of \u20ac90 000\/QALY, with probabilities of being cost-effective of 89.8%, 98.2% and 86.4%, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This analysis showed encorafenib with cetuximab to be a cost-effective treatment in mCRC patients with a BRAF V600E mutation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-063700","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T11:24:28Z","timestamp":1669029868000},"page":"e063700","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct02928224","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02928224","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1055-9858","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Trouiller","sequence":"first","affiliation":[{"name":"Department of Public Health, Aix-Marseille University, Marseille, France"},{"name":"Pierre Fabre Laboratories, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9reng\u00e8re","family":"Macabeo","sequence":"additional","affiliation":[{"name":"Department of Public Health, Aix-Marseille University, Marseille, France"},{"name":"Pierre Fabre Laboratories, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Poll","sequence":"additional","affiliation":[{"name":"Pierre Fabre Ltd, Reading, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Howard","sequence":"additional","affiliation":[{"name":"Mtech Access, Bicester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Buckland","sequence":"additional","affiliation":[{"name":"Mtech Access, Bicester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Sivignon","sequence":"additional","affiliation":[{"name":"Creativ Ceutical, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Clay","sequence":"additional","affiliation":[{"name":"Creativ Ceutical, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7664-0130","authenticated-orcid":false,"given":"David","family":"Malka","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Gustave Roussy, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Samalin","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut du Cancer de Montpellier, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mondher","family":"Toumi","sequence":"additional","affiliation":[{"name":"Creativ Ceutical, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Laram\u00e9e","sequence":"additional","affiliation":[{"name":"Department of Public Health, Aix-Marseille University, Marseille, France"},{"name":"Pierre Fabre Laboratories, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"2025101811180197000_12.11.e063700.1","unstructured":"European Commission . Colorectal caner burden in EU-27. Available: https:\/\/ecis.jrc.ec.europa.eu\/pdf\/Colorectal_cancer_factsheet-Mar_2021.pdf [Accessed 24 Aug 2022]."},{"key":"2025101811180197000_12.11.e063700.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70442-X"},{"key":"2025101811180197000_12.11.e063700.3","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"key":"2025101811180197000_12.11.e063700.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.4295"},{"key":"2025101811180197000_12.11.e063700.5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26086"},{"key":"2025101811180197000_12.11.e063700.6","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025101811180197000_12.11.e063700.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30142-6"},{"key":"2025101811180197000_12.11.e063700.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30146-2"},{"key":"2025101811180197000_12.11.e063700.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.2497"},{"key":"2025101811180197000_12.11.e063700.10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.4001","article-title":"Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)","volume":"38","author":"Kopetz","year":"2020","journal-title":"JCO"},{"key":"2025101811180197000_12.11.e063700.11","unstructured":"National Comprehensive Cancer Network . NCCN guidelines. Available: https:\/\/www.nccn.org\/guidelines\/category_1 [Accessed 24 Aug 2022]."},{"key":"2025101811180197000_12.11.e063700.12","unstructured":"European Society of Medical Oncology . ESMO pocket guidelines and mobile APP. Available: https:\/\/www.esmo.org\/guidelines\/pocket-guidelines-mobile-app [Accessed 24 Aug 2022]."},{"key":"2025101811180197000_12.11.e063700.13","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0914"},{"key":"2025101811180197000_12.11.e063700.14","unstructured":"Phelip J-M . Th\u00e9saurus National de Canc\u00e9rologie Digestive. In: Cancer colorectal m\u00e9tastatique [French], 2022. https:\/\/www.snfge.org\/sites\/default\/files\/SNFGE\/TNCD\/tncd_chap-04-cancer-colorectal-metastatique_2020-03-05-vf.pdf"},{"key":"2025101811180197000_12.11.e063700.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0606"},{"key":"2025101811180197000_12.11.e063700.16","first-page":"206","article-title":"Final analysis of outcomes and RAS\/BRAF status in a randomized phase 3 study of panitumumab and best supportive care in chemorefractory wild type KRAS metastatic colorectal cancer","volume":"17","author":"Kim","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"2025101811180197000_12.11.e063700.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1913"},{"key":"2025101811180197000_12.11.e063700.18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0526"},{"key":"2025101811180197000_12.11.e063700.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70163-3"},{"key":"2025101811180197000_12.11.e063700.20","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13098"},{"key":"2025101811180197000_12.11.e063700.21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mdy461","article-title":"Biomarker analysis beyond angiogenesis: Ras\/Raf mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study","volume":"30","author":"Yoshino","year":"2019","journal-title":"Ann Oncol"},{"key":"2025101811180197000_12.11.e063700.22","unstructured":"National Institute for Health and Care Excellence . Single Technology Appraisal: Encorafenib in dual or triple therapy for previously treated BRAF V600E mutationpositive metastatic colorectal cancer [ID1598]. Committee Papers. Available: https:\/\/www.nice.org.uk\/guidance\/ta668\/evidence\/appraisal-consultation-committee-papers-pdf-8955945757 [Accessed 24 Aug 2022]."},{"key":"2025101811180197000_12.11.e063700.23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jamaoncol.2018.4465","article-title":"Continuation of bevacizumab vs cetuximab plus chemotherapy after first progression in KRAS wild-type metastatic colorectal cancer: the UNICANCER prodige18 randomized clinical trial","volume":"5","author":"Bennouna","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025101811180197000_12.11.e063700.24","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamaoncol.2017.5314","article-title":"Activity and safety of cetuximab plus modified FOLFOXIRI followed by maintenance with cetuximab or bevacizumab for ras and BRAF wild-type metastatic colorectal cancer: a randomized phase 2 clinical trial","volume":"4","author":"Cremolini","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025101811180197000_12.11.e063700.25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70330-4"},{"key":"2025101811180197000_12.11.e063700.26","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1200\/JCO.18.01798","article-title":"Mutational analysis of patients with colorectal cancer in CALGB\/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome","volume":"37","author":"Innocenti","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025101811180197000_12.11.e063700.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0518-2"},{"key":"2025101811180197000_12.11.e063700.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.03.023"},{"key":"2025101811180197000_12.11.e063700.29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7105"},{"key":"2025101811180197000_12.11.e063700.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.06.012"},{"key":"2025101811180197000_12.11.e063700.31","unstructured":"Latimer N . NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. Available: http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf [Accessed 24 Aug 2022]."},{"key":"2025101811180197000_12.11.e063700.32","unstructured":"Sant\u00e9 HAde . Choix m\u00e9thodologiques pour l'\u00e9valuation \u00e9conomique La has. Available: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-07\/guide_methodologique_evaluation_economique_has_2020_vf.pdf [Accessed 24 Aug 2022]."},{"key":"2025101811180197000_12.11.e063700.33","unstructured":"Woods BS , Sideris E , Palmer SJ . Nice dsu technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. Available: https:\/\/pure.york.ac.uk\/portal\/en\/publications\/nice-dsu-technical-support-document-19(4abca204-a8a5-4880-9cce-190049a1daf9)\/export.html [Accessed 24 Aug 2022]."},{"key":"2025101811180197000_12.11.e063700.34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025101811180197000_12.11.e063700.35","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2019.1711169"},{"key":"2025101811180197000_12.11.e063700.36","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw402"},{"key":"2025101811180197000_12.11.e063700.37","unstructured":"EuroQuol . EQ-5D-5L. Available: https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/ [Accessed 24 Aug 2022]."},{"key":"2025101811180197000_12.11.e063700.38","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X8500500205"},{"key":"2025101811180197000_12.11.e063700.39","unstructured":"WHO . Making choices in health: WHO guide to cost-e\ufb00ectiveness analysis. In: Tan-Torres Edejer T , Baltussen R , Adam T , et al , eds. Geneva: WHO, 2003."},{"key":"2025101811180197000_12.11.e063700.40","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.33441","article-title":"Evaluation of the cost-effectiveness of doublet therapy in metastatic BRAF variant colorectal cancer","volume":"4","author":"Patel","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025101811180197000_12.11.e063700.41","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1007\/s12325-021-01627-8","article-title":"Cost-effectiveness analysis of encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated metastatic colorectal cancer in the USA","volume":"38","author":"Li","year":"2021","journal-title":"Adv Ther"},{"key":"2025101811180197000_12.11.e063700.42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/10781552211045006","article-title":"Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer","volume":"28","author":"Giuliani","year":"2022","journal-title":"J Oncol Pharm Pract"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-063700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:18:11Z","timestamp":1760811491000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-063700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,21]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/bmjopen-2022-063700"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-063700","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}